Related Experiment Video
Updated: Aug 17, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems
A B Dessens1, P T Cohen-Kettenis, G J Mellenbergh
1Academic Medical Center, University of Amsterdam, Graduate School Neurosciences, The Netherlands.
Insights
Prenatal exposure to anticonvulsants like phenobarbital and phenytoin can affect fetal head size. While cognitive function in adulthood may be normal, some exposed individuals experience learning problems or mental retardation.
Area of Science:
- Neuroscience
- Developmental Psychology
- Pharmacology
Background:
- Prenatal exposure to anticonvulsant medications is associated with developmental abnormalities.
- Cognitive impairments observed in infancy following prenatal anticonvulsant exposure raise questions about long-term effects.
- The persistence of these cognitive deficits into adulthood remains largely uninvestigated.
Purpose of the Study:
- To investigate the long-term effects of prenatal anticonvulsant exposure on cognitive functioning in adulthood.
- To examine the relationship between prenatal anticonvulsant exposure, head size, and cognitive outcomes in adults.
- To determine if cognitive impairments observed in infancy persist after puberty.
Main Methods:
- A retrospective study involving 172 neonates exposed prenatally to anticonvulsants and 168 matched controls.
- Measurement of occipitofrontal circumference (OFC) in neonates to assess head size.
- A follow-up assessment of cognitive capacities in adulthood for individuals included in the retrospective study.
Main Results:
- Prenatal exposure to phenobarbital + phenytoin resulted in a significantly smaller occipitofrontal circumference (OFC) compared to controls.
- No overall difference in cognitive functioning was found between the exposed and control groups in adulthood.
- A higher prevalence of persistent learning problems (12% vs 1%) and mental retardation was observed in the exposed group.
Conclusions:
- The combination of phenobarbital and phenytoin impacts fetal head development (OFC).
- A smaller OFC in exposed individuals did not correlate with cognitive functioning in adulthood.
- Prenatal anticonvulsant exposure may increase the risk for learning difficulties and mental retardation in susceptible individuals.
Unlabelled:
Small head size has been observed in prenatally anticonvulsant-exposed neonates. In infancy, cognitive impairments were revealed. It is presently unknown whether these impairments are permanent or disappear after puberty. We studied the link between the prenatal influence of anticonvulsants on brain development and cognitive functioning in adulthood: a retrospective study on head size and a follow-up assessing cognitive capacities among adults who had been included in the retrospective study. The retrospective study comprised 172 exposed and 168 control neonates, matched with respect to age, sex and their mothers' age. Prenatally phenobarbital + phenytoin-exposed neonates had a significantly smaller occipitofrontal circumference (OFC) than prenatally phenobarbital-monotherapy-exposed and control neonates (mean difference of 0.7 cm). In the follow-up, no difference in cognitive functioning was found between the exposed and the control groups. Most of the prenatally anticonvulsant-exposed subjects had normal intellectual capacity. However, 12% of the exposed subjects versus 1% of the controls had persistent learning problems. In addition, more of the exposed subjects were mentally retarded. There was no clear relationship between learning problems and small OFC, maternal epilepsy or unfavourable family climate.
Conclusions:
We conclude that the combination of phenobarbital + phenytoin affects the fetal OFC. The smaller OFC does not seem to be related to cognitive functioning in adulthood, but learning problems and mental retardation proved to be more prevalent among exposed subjects. Phenobarbital and phenytoin may therefore affect cognitive capacity but only in infants who are susceptible to this particular influence of the drugs.
More Related Videos
Related Concept Videos
Teratogenicity
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.

